Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1376833 | Bioorganic & Medicinal Chemistry Letters | 2008 | 7 Pages |
Abstract
A new series of EP4 antagonists based on a quinoline acylsulfonamide scaffold have been identified as part of our on-going efforts to develop treatments for chronic inflammation. These compounds show subnanomolar intrinsic binding potency towards the EP4 receptor, and excellent selectivity towards other prostanoid receptors. Acceptable pharmacokinetic profiles have also been demonstrated across a series of preclinical species.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Jason D. Burch, Michel Belley, Réjean Fortin, Denis Deschênes, Mario Girard, John Colucci, Julie Farand, Alex G. Therien, Marie-Claude Mathieu, Danielle Denis, Erika Vigneault, Jean-François Lévesque, Sébastien Gagné, Mark Wrona, Daigen Xu, Patsy Clark,